Want to see KR:207940 full AI Analyst Report?
Top Page
SAMSUNG BIOLOGICS Co., Ltd.
(207940)
Select Model
Select Model
Rating:70Outperform
Price Target:
$1,511,400
Action:N/A
Date:10/28/26
The score is primarily supported by strong financial performance—rapid recent growth, very high margins, and low leverage. Offsetting this, the technical picture is mixed (below key longer-term moving averages with neutral momentum), and valuation is relatively expensive (P/E ~35) with no dividend yield provided.
Positive Factors
Strong growth and margins
Accelerating revenue and very high profitability indicate strong demand for Samsung Biologics’ services and meaningful operating scale. If sustained, this combination can support reinvestment, strengthen competitive positioning, and expand earnings capacity over the next several quarters.
Negative Factors
Uneven free cash flow history
Current cash generation is strong, but prior negative and weak free-cash-flow periods show that accounting profits have not converted consistently across cycles. This may make internally funded expansion less predictable and increases the importance of disciplined investment and working-capital management.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong growth and margins
Accelerating revenue and very high profitability indicate strong demand for Samsung Biologics’ services and meaningful operating scale. If sustained, this combination can support reinvestment, strengthen competitive positioning, and expand earnings capacity over the next several quarters.
Read all positive factors
SAMSUNG BIOLOGICS Co., Ltd. (207940) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩71.54T
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)38.3
Beta (1Y)0.16
Revenue Growth-20.49%
EPS Growth12.95%
CountryKR
Employees5,455
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)42889.19
Shares Outstanding48,108,982
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)10.52
Price to Sales (P/S)17.20
P/FCF Ratio91.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₩1,550,000.00Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)39,430.5
Revenue Forecast (FY)₩5.55T
SAMSUNG BIOLOGICS Co., Ltd. Business Overview & Revenue Model
Company Description
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization ...
SAMSUNG BIOLOGICS Co., Ltd. Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
84
Very Positive
Cash Flow
76
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.55T | 4.56T | 3.50T | 3.69T | 3.00T | 1.57T |
| Gross Profit | 2.53T | 2.48T | 1.68T | 1.77T | 1.44T | 784.97B |
| EBITDA | 2.95T | 2.78T | 2.03T | 1.69T | 1.38T | 737.78B |
| Net Income | 1.98T | 1.78T | 1.08T | 857.69B | 798.06B | 393.59B |
Balance Sheet | ||||||
| Total Assets | 12.65T | 11.06T | 17.34T | 16.05T | 16.58T | 7.97T |
| Cash, Cash Equivalents and Short-Term Investments | 2.19T | 1.46T | 1.33T | 2.06T | 3.19T | 1.37T |
| Total Debt | 1.24T | 928.21B | 1.49T | 1.91T | 2.51T | 1.29T |
| Total Liabilities | 4.29T | 3.61T | 6.43T | 6.22T | 7.60T | 2.98T |
| Stockholders Equity | 8.36T | 7.45T | 10.90T | 9.83T | 8.98T | 4.99T |
Cash Flow | ||||||
| Free Cash Flow | 1.61T | 856.07B | 281.73B | 560.90B | -56.18B | 33.44B |
| Operating Cash Flow | 2.43T | 2.25T | 1.66T | 1.67T | 953.05B | 454.60B |
| Investing Cash Flow | -2.39T | -1.86T | -1.24T | -1.57T | -3.11T | -933.49B |
| Financing Cash Flow | -510.64B | -620.50B | -433.79B | -635.05B | 3.00T | 496.62B |
SAMSUNG BIOLOGICS Co., Ltd. Technical Analysis
Positive
―
Price Trends
1411904.54
Positive
1408651.79
Positive
1504985.40
Negative
Market Momentum
11066.77
Negative
59.63
Neutral
66.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:207940, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 1341318.22, equal to the 50-day MA of 1411904.54, and equal to the 200-day MA of 1504985.40, indicating a neutral trend. The MACD of 11066.77 indicates Negative momentum. The RSI at 59.63 is Neutral, neither overbought nor oversold. The STOCH value of 66.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KR:207940.
SAMSUNG BIOLOGICS Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
KR:207940
SAMSUNG BIOLOGICS Co., Ltd.
1,487,000.00
-297,882.90
-16.69%
KR:196170
ALTEOGEN Inc.
211,500.00
-163,951.78
-43.67%
KR:214450
PharmaResearch Co., Ltd.
212,000.00
-327,427.75
-60.70%
KR:298380
ABL Bio, Inc.
39,200.00
-60,500.00
-60.68%
KR:302440
SK bioscience Co.,Ltd.
32,750.00
-17,950.00
-35.40%
KR:347850
D&D Pharmatech Co., Ltd.
40,850.00
-28,650.00
-41.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.